Belite Bio, Inc
BLTE
Kedudukan dalam Saham
#3054
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Harga Saham
$148.24
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.97B
Perubahan (1 hari)
3.82%
Perubahan (1 tahun)
64.04%
Negara
US
Perdagangan Belite Bio, Inc (BLTE)
Kategori
Healthcare
Nisbah P/S bagi Belite Bio, Inc (BLTE)
Nisbah P/S pada October 2026 TTM: 0.00
Menurut laporan kewangan dan harga saham terkini Belite Bio, Inc, nisbah P/S semasa (TTM) ialah 0.00. Pada akhir 2023, nisbah P/S syarikat ialah 0.00.
Sejarah nisbah P/S untuk Belite Bio, Inc dari 2020 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
